Forxiga (dapagliflozin)

pCPA File Number: 21379

Negotiation Status:

Concluded with an LOI

Indication(s):

Heart failure, NYHA class II or III

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CDA-AMC Project Number:

SR0642-000

pCPA Engagement Letter Issued:

2021-06-17

Negotiation Process Concluded:

2021-11-18